Which drug first? new trial aims to improve survival in tough colorectal cancer
NCT ID NCT04787341
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two different sequences of the drugs panitumumab and regorafenib in 214 patients with advanced colorectal cancer that no longer responds to standard treatments. The goal is to see which order of these drugs helps patients live longer. Participants must have previously benefited from an anti-EGFR therapy and have no RAS or BRAF mutations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Panitumumab and regorafenib
What this could lead to
If successful, this trial could help determine the best order of these two drugs to extend survival in patients with advanced colorectal cancer who have run out of standard options.
What could go wrong
This is a phase 2 trial with only 214 participants, so results are not definitive. The drugs can cause side effects like skin reactions, fatigue, and liver issues, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
U.O. Oncologia 2 Universitaria
Pisa, PI, 56126, Italy